Last reviewed · How we verify
6-Mercaptopurine (6-mercaptopurine)
6-Mercaptopurine (generic name: 6-mercaptopurine) is a drug developed by Pfizer Inc.. It is currently FDA-approved for Acute lymphoid leukemia, Acute promyelocytic leukemia, FAB M3.
6-Mercaptopurine, also known as Purinethol, is a small molecule medication used to treat acute lymphocytic leukemia (ALL) and other conditions such as Crohn's disease and ulcerative colitis. It is typically taken orally and is often used in combination with other medications, including methotrexate, for the treatment of ALL.
At a glance
| Generic name | 6-mercaptopurine |
|---|---|
| Sponsor | Pfizer Inc. |
| Target | Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia
- Acute promyelocytic leukemia, FAB M3
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE2)
- Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6-Mercaptopurine CI brief — competitive landscape report
- 6-Mercaptopurine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about 6-Mercaptopurine
What is 6-Mercaptopurine?
What is 6-Mercaptopurine used for?
Who makes 6-Mercaptopurine?
What is the generic name of 6-Mercaptopurine?
What development phase is 6-Mercaptopurine in?
What does 6-Mercaptopurine target?
Related
- Target: All drugs targeting Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute lymphoid leukemia
- Indication: Drugs for Acute promyelocytic leukemia, FAB M3
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing